IL1B and diabetes mellitus: Various IL-1β-targeting agents such as IL-1 receptor antagonist, soluble decoy receptor and neutralizing monoclonal anti-IL-1β antibody have been used with success in several inflammatory diseases such as rheumatisms, diabetes and cancers in humans [1, 2].